Paola Aimone, MD

Novartis Pharma
Basel Switzerland Papers:
792 Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial